RPI-1
RPI-1 is a specific, orally available 2-indolinone Ret tyrosine kinase inhibitor. RPI-1 inhibits proliferation, Ret tyrosine phosphorylation, Ret protein expression, and the activation of PLCgamma, ERKs and AKT in human medullary thyroid carcinoma TT cells. Antitumor activity[1].
Product Specifications
CAS Number
269730-03-2
UNSPSC
12352005
Hazard Statement
H400
Target
RET
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/rpi-1.html
Purity
99.29
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
O=C1NC2=C(C=C(OC)C(OC)=C2)/C1=C/C3=CC=C(O)C=C3
Molecular Formula
C17H15NO4
Molecular Weight
297.31
Precautions
P273-P391-P501
References & Citations
[1]Lanzi C, et al. Inactivation of Ret/Ptc1 oncoprotein and inhibition of papillary thyroid carcinoma cell proliferation by indolinone RPI-1. Cell Mol Life Sci. 2003;60 (7) :1449-1459.|[2]Cuccuru G, et al. Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma. J Natl Cancer Inst. 2004;96 (13) :1006-1014.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
